| IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy V Suppiah, M Moldovan, G Ahlenstiel, T Berg, M Weltman, ML Abate, ... Nature genetics 41 (10), 1100-1104, 2009 | 2372 | 2009 |
| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2074 | 2017 |
| Epidemiology and natural history of HCV infection B Hajarizadeh, J Grebely, GJ Dore Nature reviews Gastroenterology & hepatology 10 (9), 553-562, 2013 | 1291 | 2013 |
| Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression HH Thein, Q Yi, GJ Dore, MD Krahn Hepatology 48 (2), 418-431, 2008 | 1115 | 2008 |
| Estimating progression to cirrhosis in chronic hepatitis C virus infection AJ Freeman, GJ Dore, MG Law, M Thorpe, J Von Overbeck, AR Lloyd, ... Hepatology 34 (4), 809-816, 2001 | 899 | 2001 |
| Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection C Phetsouphanh, DR Darley, DB Wilson, A Howe, C Munier, SK Patel, ... Nature immunology 23 (2), 210-216, 2022 | 664 | 2022 |
| Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised … IM Jacobson, GJ Dore, GR Foster, MW Fried, M Radu, VV Rafalsky, ... The Lancet 384 (9941), 403-413, 2014 | 635 | 2014 |
| Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals NK Martin, P Vickerman, J Grebely, M Hellard, SJ Hutchinson, VD Lima, ... Hepatology 58 (5), 1598-1609, 2013 | 591 | 2013 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 558 | 2014 |
| Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis HH Thein, Q Yi, GJ Dore, MD Krahn Aids 22 (15), 1979-1991, 2008 | 519 | 2008 |
| Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression R Waziry, B Hajarizadeh, J Grebely, J Amin, M Law, M Danta, J George, ... Journal of hepatology 67 (6), 1204-1212, 2017 | 506 | 2017 |
| The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection J Grebely, K Page, R Sacks‐Davis, MS van der Loeff, TM Rice, J Bruneau, ... Hepatology 59 (1), 109-120, 2014 | 501 | 2014 |
| Changes to AIDS dementia complex in the era of highly active antiretroviral therapy GJ Dore, PK Correll, Y Li, JM Kaldor, DA Cooper, BJ Brew Aids 13 (10), 1249-1253, 1999 | 501 | 1999 |
| Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States S Barua, R Greenwald, J Grebely, GJ Dore, T Swan, LE Taylor Annals of internal medicine 163 (3), 215-223, 2015 | 488 | 2015 |
| Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection S Zeuzem, GR Foster, S Wang, A Asatryan, E Gane, JJ Feld, T Asselah, ... New England Journal of Medicine 378 (4), 354-369, 2018 | 470 | 2018 |
| Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ... Annals of internal medicine 165 (9), 625-634, 2016 | 415 | 2016 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 411 | 2014 |
| Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden VTT Nguyen, MG Law, GJ Dore Journal of viral hepatitis 16 (7), 453-463, 2009 | 394 | 2009 |
| Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis EJ Aspinall, S Corson, JS Doyle, J Grebely, SJ Hutchinson, GJ Dore, ... Clinical Infectious Diseases 57 (suppl_2), S80-S89, 2013 | 390 | 2013 |
| Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naive genotype 1 hepatitis C: the randomized PILLAR study MW Fried, M Buti, GJ Dore, R Flisiak, P Ferenci, I Jacobson, P Marcellin, ... Hepatology 58 (6), 1918-1929, 2013 | 374 | 2013 |
Jason GrebelyProfessor, The Kirby Institute, UNSW SydneyVerified email at kirby.unsw.edu.au
